Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGEND001 in Interstitial Lung Disease
NCT06998706Phase 1Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jun 2025
- Primary completion
- Jun 2029
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous bronchial basal cells in interstitial lung disease (ILD), sponsored by Ruijin Hospital. Primary endpoint: Diffusing Capacity of the Lungs for Carbon Monoxide at 24 weeks. Started Jun 2025; status: recruiting.
02
Drugs
autologous bronchial basal cells
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT06998706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06998706.